Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20521874 | 0.93 | KDM1A (0.48) | KDM1ARAB9ASMN1; SMN2MAOBMAPT | |
| SCHEMBL30221893 | 0.93 | KDM1A (0.48) | KDM1ARAB9ASMN1; SMN2MAOBMAPT | |
| SCHEMBL31166845 | 0.90 | RAB9A (0.49) | KDM1ARAB9ASMN1; SMN2MAOBMAPT | |
| SCHEMBL16636496 | 0.88 | RAB9A (0.50) | KDM1ARAB9ASMN1; SMN2MAOBMAPT | |
| SCHEMBL23048779 | 0.85 | KDM1A (0.48) | KDM1ARAB9ASMN1; SMN2MAOBMAPT | |
| SCHEMBL21835674 | 0.85 | MRGPRX4 (0.53) | KDM1ARAB9ASMN1; SMN2MAOBMAPT | |
| SCHEMBL21835660 | 0.85 | MAPT (0.49) | KDM1ARAB9ASMN1; SMN2MAOBMAPT | |
| SCHEMBL18556063 | 0.85 | RAB9A (0.46) | KDM1ARAB9ASMN1; SMN2MAOBMAPT | |
| SCHEMBL30443242 | 0.84 | CTSV (0.53) | RAB9ASMN1; SMN2MAPTL3MBTL1NPC1 | |
| SCHEMBL4970541 | 0.84 | CTSV (0.53) | RAB9ASMN1; SMN2MAPTL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| WO-2017044877-A1 | PHENETHYLDIHYDROBENZODIOXOLONES AND METHODS OF USE | SEQUOIA SCIENCES, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017044877-A1 | PHENETHYLDIHYDROBENZODIOXOLONES AND METHODS OF USE | SEQUOIA SCIENCES, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-9562031-B1 | Phenethyldihydrobenzodioxolones and methods of use | SEQUOIA SCIENCES, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-3088400-A1 | PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON INC. (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| EP-2395004-B1 | Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors | PLEXXIKON INC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC | 2008-09-11 | — | — | US | disclosed |
| WO-2008080015-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1893612-A1 | PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2008-03-05 | — | — | EP | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1844026-A2 | MORPHOLINES AS 5HT2C AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007002325-A1 | PYRROLO[2,3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002433-A1 | PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | PLEXXIKON, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006077025-A2 | MORPHOLINES AS 5HT2C AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| WO-1994010179-A1 | ARYLBORON ACIDS AS INTERMEDIATES IN THE PRODUCTION OF COMPONENTS OF LIQUID-CRYSTAL MIXTURES | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KDM1A 2465/4885RAB9A 1597/4885SMN1; SMN2 1839/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KDM1A 2465/4885RAB9A 1597/4885SMN1; SMN2 1839/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KDM1A 2465/4885RAB9A 1597/4885SMN1; SMN2 1839/4885 |
| US-20080221148-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KDM1A 2465/4885RAB9A 1597/4885SMN1; SMN2 1839/4885 |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HTR2C, HTR1A, HTR1B | KDM1A 1231/4885RAB9A 2441/4885SMN1; SMN2 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.